Tryptamine Therapeutics Advances Psilocin Drug Trials
Company Announcements

Tryptamine Therapeutics Advances Psilocin Drug Trials

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics has announced that their Phase 1b study of TRP-8803, an IV-infused psilocin formulation, has been deemed safe by the Safety Review Council. This milestone paves the way for further clinical trials, building on promising results from previous studies using their oral psilocybin treatment, TRP-8802. The company aims to advance its innovative psilocin-based therapies, targeting conditions with unmet medical needs.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App